Hardman Research: Expanding global distribution

Hardman Research: Expanding global distribution network

Expanding global distribution network: Premaitha uses the latest advances in DNA sequencing technology for non-invasive prenatal screening tests. IONA uses complex statistical analyses to determine the likelihood that a fetus is carrying a disorder such as Down's syndrome or other prenatal genetic abnormalities. The opportunity to grow IONA in Asian markets is well recognised and the strategic acquisition of Yourgene Bioscience will accelerate this. Meanwhile, Premaitha has moved quickly to expand the availability of IONA throughout Europe and the Middle East, thereby offsetting the impact of financial difficulties being encountered by its largest customer in fiscal 2017. 

Please click here for the full report:

http://hardmanandco.com/docs/default-source/company-docs/premaitha-health-plc-documents/17.03.17-expanding-global-distribution-network.pdf

www.hardmanandco.com

About Hardman & Co: For the past 20 years Hardman has been producing specialist research designed to improve investors' understanding of companies, sectors, industries and investment securities. Our analysts are highly experienced in their sectors, and have often been highly rated by professional investors for their knowledge. Our focus is to raise companies' profiles across the UK and abroad with outstanding research, investor engagement programmes and advisory services. Some of our notes have been commissioned by the company which is the subject of the note; this is clearly stated in the disclaimer where this is the case.

Hardman Research Ltd, trading as Hardman & Co, is an appointed representative of Capital Markets Strategy Ltd and is authorised and regulated by the Financial Conduct Authority; our FCA registration number is 600843. Hardman Research Ltd is registered at Companies House with number 8256259.

Our research is provided for the use of the professional investment community, market counterparties and sophisticated and high net worth investors as defined in the rules of the regulatory bodies. It is not intended to be made available to unsophisticated retail investors. Anyone who is unsure of their categorisation should consult their professional advisors. This research is neither an offer, nor a solicitation, to buy or sell any security. Please read the note for the full disclaimer.